Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.36 |
| ▸ | PNMT | P11086 | 4/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014903 | 1.00 | HTR2C (0.40) | HTR2CHTR2BCYP3A4POLBSMN1; SMN2 | |
| SCHEMBL26962889 | 0.85 | HTR2C (0.41) | HTR2CHTR2BASIC3PNMTCD44 | |
| SCHEMBL16058900 | 0.82 | CYP1A2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL17499088 | 0.81 | CYP1A2 (0.30) | — | |
| SCHEMBL14637187 | 0.79 | CYP3A4 (0.38) | HTR2CHTR2BCYP3A4POLBSMN1; SMN2 | |
| SCHEMBL4407148 | 0.78 | PNMT (0.41) | HTR2CHTR2BCYP3A4POLBSMN1; SMN2 | |
| SCHEMBL722943 | 0.78 | PNMT (0.50) | HTR2CCYP3A4POLBSMN1; SMN2ASIC3 | |
| SCHEMBL694665 | 0.78 | PNMT (0.50) | HTR2CHTR2BCYP3A4POLBSMN1; SMN2 | |
| SCHEMBL13226202 | 0.78 | MB (0.40) | HTR2CCYP3A4POLBSMN1; SMN2ASIC3 | |
| SCHEMBL5457714 | 0.78 | CYP3A4 (0.40) | HTR2CCYP3A4POLBSMN1; SMN2ASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024067819-A1 | PIPERIDINE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| EP-4291177-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | Recovery Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117157069-A | Compounds, compositions and methods for modulating FGF activity | 康复治疗公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022174083-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2013010453-A1 | CHEMOKING RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | HTR2C 1517/4885HTR2B 2151/4885CYP3A4 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.